This study evaluates the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine’s effect over time among adolescents 11 to 18 years old and accounts for the transition from whole-cell to acellular pertussis vaccines for the childhood primary series.
This secondary analysis of a vaccine efficacy trial evaluates the duration of infant protection against influenza conferred by maternal immunization.
This review article summarizes the role of innate immunity in influenza A virus infection in the young child and highlights possible differences between children and adults that may make children more susceptible to severe influenza A infection.
This cohort study found an increase in adverse events after immunization of extremely low-birth-weight infants in the neonatal intensive care unit.
This randomized pragmatic trial reports improved rates of up-to-date immunizations when primary care practices instituted a collaborative centralized reminder/recall. See also the Editorial comment by Fiks.
This retrospective study demonstrates a significant practice change in the management of newly diagnosed immune thrombocytopenia at a pediatric care tertiary care hospital surrounding revision of management guidelines for childhood immune thrombocytopenia from the American Society of Hematology.
Rowhani-Rahbar et al examine the potential modifying effect of age on the risk of fever and seizures following immunization with measles-containing vaccines.
Opel et al determine the predictive validity and test-retest reliability of the Parent Attitudes About Childhood Vaccines survey, a recently developed measure of vaccine hesitancy.
This review provides an overview of measles, including information on virus basics, clinical picture and diagnosis, complications, vaccine efficacy, and vaccine complications.
This retrospective analysis reports that the incidence of IPD in NYC children younger than 5 years and, particularly, the incidence of IPD caused by serotype 19A decreased dramatically following the introduction of PCV13, with reductions among all age and racial/ethnic groups. This represents a significant achievement for public health immunization programs and underscores the importance of achieving high immunization coverage.